Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Herrmann R, et al. Among authors: bauer j. J Clin Oncol. 2007 Jun 1;25(16):2212-7. doi: 10.1200/JCO.2006.09.0886. J Clin Oncol. 2007. PMID: 17538165 Clinical Trial.
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. Bernhard J, et al. Among authors: bauer j. J Clin Oncol. 2008 Aug 1;26(22):3695-701. doi: 10.1200/JCO.2007.15.6240. J Clin Oncol. 2008. PMID: 18669454 Clinical Trial.
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Morant R, Bernhard J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J, Cerny T, Rochlitz C, Wernli M, Gschwend A, Hanselmann S, Hering F, Schmid HP. Morant R, et al. Among authors: bauer j. Br J Cancer. 2004 Apr 5;90(7):1312-7. doi: 10.1038/sj.bjc.6601673. Br J Cancer. 2004. PMID: 15054447 Free PMC article. Clinical Trial.
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
Morant R, Bernhard J, Maibach R, Borner M, Fey MF, Thürlimann B, Jacky E, Trinkler F, Bauer J, Zulian G, Hanselmann S, Hürny C, Hering F. Morant R, et al. Among authors: bauer j. Ann Oncol. 2000 Feb;11(2):183-8. doi: 10.1023/a:1008332724977. Ann Oncol. 2000. PMID: 10761753 Free article. Clinical Trial.
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S, Sperka S, Sessa C. Gallerani E, et al. Among authors: bauer j. Acta Oncol. 2011 Oct;50(7):1105-10. doi: 10.3109/0284186X.2010.543697. Epub 2010 Dec 27. Acta Oncol. 2011. PMID: 21184645 Clinical Trial.
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Pagani O, Sessa C, Nolè F, Crivellari D, Lombardi D, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A. Pagani O, et al. Among authors: bauer j. Ann Oncol. 2000 Aug;11(8):985-91. doi: 10.1023/a:1008392927656. Ann Oncol. 2000. PMID: 11038035 Free article. Clinical Trial.
4,404 results